Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Clover Health Investments' Interim CFO, Joseph Clay, reported a routine tax-withholding event tied to restricted stock units. On April 15, 2026, 4,158 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover taxes when 6.25% of an RSU grant vested.
The RSUs were originally granted on October 15, 2024 and continue to vest in equal 6.25% quarterly installments through October 15, 2028, as long as Clay remains in service. After this non-market tax-withholding disposition, he directly holds 1,234,526 shares of Class A Common Stock.
Clover Health Investments executive Jamie L. Reynoso reported an automatic share disposition tied to equity compensation. On April 15, 2026, 12,712 shares of Class A Common Stock were withheld at $2.04 per share to cover tax obligations from vesting restricted stock units (RSUs). After this tax-withholding event, Reynoso directly holds 2,857,210 shares of Class A Common Stock. The footnote explains that this reflects 6.25% of an RSU grant made on October 15, 2024, with the remaining RSUs scheduled to vest in equal 6.25% quarterly installments through October 15, 2028, contingent on continued service.
Clover Health Investments, Corp. reported an insider equity event involving executive Conrad Wai. On April 15, 2026, 23,463 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover tax obligations arising from the vesting of restricted stock units granted in October 2024.
The vested portion represented 6.25% of the original RSU grant, with additional 6.25% installments scheduled to vest quarterly through October 15, 2028, subject to continued service. Following this tax-withholding disposition, Wai holds 1,169,914 shares directly and 1,610,482 shares indirectly through a family trust where he is co-trustee.
Clover Health Investments, Corp. executive Joseph Frank Oldakowski, Vice President of Finance and Controller, filed an initial ownership report. He beneficially owns 311,169 shares of Class A common stock underlying unvested time-based restricted stock units as of March 30, 2026. These restricted stock units were originally granted on June 16, 2025 and December 19, 2025, reflecting equity-based compensation rather than recent open-market trading.
Clover Health Investments (CLOV) interim CFO Joseph Clay Thornton reported his equity holdings in an amended Form 3. He beneficially owns 1,238,684 shares of Class A common stock directly. This total includes 912,860 shares underlying the remaining unvested portion of time-based restricted stock unit awards as of March 30, 2026, originally granted on February 16, 2024, October 15, 2024 and December 19, 2025.
Clover Health Investments Interim CFO Joseph Clay reported his initial beneficial ownership on a Form 3. He shows 1,238,684 shares of Class A common stock held directly, including 912,860 shares underlying the remaining unvested portion of restricted stock unit awards granted on February 16, 2024, October 15, 2024 and December 19, 2025.
Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, had 6,197 shares of Class A Common Stock withheld on April 3, 2026 to cover tax obligations. The withholding related to the vesting of 6.25% of restricted stock units granted on January 3, 2023.
After this tax-withholding disposition, Reynoso directly holds 2,869,922 shares of Class A Common Stock. The remaining RSUs from the 2023 grant will vest in equal quarterly installments through January 3, 2027, subject to Reynoso’s continued service on each vesting date.
Priest Brady Patrick reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments insider Brady Patrick Priest, CEO of Clover Care Services, received an award of 191,261 shares of Class A Common Stock in the form of time-based restricted stock units. These RSUs were granted at no cash purchase price as part of his equity compensation.
After this award, Priest directly holds 2,189,845 shares of Class A Common Stock. Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026, and the remaining units will vest in twelve equal quarterly installments, becoming fully vested on April 1, 2030, assuming his continued service.
Reynoso Jamie L. reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that Jamie L. Reynoso, CEO of Medicare Advantage, received a grant of 159,384 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost per share as equity compensation.
According to the grant terms, 25% of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will vest in twelve equal quarterly installments starting three months after that first anniversary, so that all RSUs are fully vested by April 1, 2030, subject to continued service. Following this award, Reynoso directly holds 2,876,119 shares of Class A common stock.
Clover Health Investments Chief Executive Officer Andrew Toy reported equity compensation changes involving Class A Common Stock. He received a grant of 956,307 shares underlying time-based restricted stock units, with 25% vesting on the first anniversary of April 1, 2026 and the remainder vesting in 12 equal quarterly installments until April 1, 2030, subject to continued service. On the same date, 309,558 shares were automatically withheld at $1.76 per share to cover tax obligations from the vesting of earlier RSUs granted January 1, 2023. After these transactions, he directly holds 10,069,770 shares of Class A Common Stock.